Laetrile – The Answer to Cancer?

Written by SOUTH, MA, James

The anti-cancer drug Laetrile is one of the most controversial subjects in the history of medicine. Laetrile's most ardent proponents consider it to be a natural cancer cure, literally built in to the normal "vitamin architecture" of mammalian food supplies as the primary natural exogenous cancer control for humans and animals. They have called Laetrile "vitamin B17," ("I"), Laetrile's opponents consider it, quite simply, as a "toxic drug that is not effective as a cancer treatment."

The term "Laetrile" was coined by the father/son team of Ernest T. Krebs Sr., M.D., and E.T. Krebs Jr. research biochemist. It is a contraction of the more formal name "L-ATA=mandelonitrile(?)BLE glucosides" for over the past 40 years the chemical identity of Laetrile has changed, as the Merck Index notes: "The name amygdalin is currently used interchangeably with Laetrile....Amygdalin is that most common constituents of Laetrile (# preparations." (2) Amygdalin is actually d-mandelonitrile b-glucoside, equivalent to the Krebs' original Laetrile plus one extra sugar molecule [See Figure 1].

Both amygdalin and the original Krebs' Laetrile (also called "laetrilurgin") are members of the class of beta-cyanogenetic glucosides, which includes others such as prunasin, dhurrin, and taxiphyllin, also calling them "nitrilosides". Krebs Jr. has defined them as "...water soluble, essentially non-toxic, sugar-containing chemicals found in...plants, many of which are edible.... They comprise molecules made of a sugar, hydrogen cyanide, a benzene ring or an acetone." (1) Krebs considers the class of nitrilosides to collectively constitute "a primary, non-toxic, water-soluble, antineoplastic principle" (Antineoplastic="...cancer-preventing plants." There are approximately 14 naturally occurring nitrilosides distributed in over 1,200 species of plants... No area on the earth that supports vegetation lacks nitriloside containing plants... From the nitriloside rich edelweiss flowers of the Arctic tundra to the arrow-grass growing in arctic marshes and supplying the sugar fodder for the caribou, to the cassava or manioc – the bread of the tropics – plants extraordinarily rich in nitrilosides, and serving as food for man and animals, are found in abundance." (3)

As Krebs points out, "Fifteen in the Kanakuruma of West Pakistan [the Hunzas], the aboriginal Eskimos, tribes of South Africa and South America living on native foods, the North American Indian in his native state, the Australian aborigines and other native or so-called primitive peoples rely upon a diet containing no more as 250 to 1000 mg of nitriloside in a daily ration. Civilized, Westernized... man, on the other hand relies on a diet that probably provides on average less than 2 mg nitriloside a day." (3) Among the U.S. cancer rank, is even one study that can be cited as evidence that man has been the victim of vitamin deficiency disease, when fatmed medical nutritionist in the 1920s – 30s, failed to discover a single case of cancer among the Hunzas during a 20 year period, while John Clark, M.D., a later medical missionary among the Hunza, also failed to find cancer among them. (3) The Hunza diet is based in significant part upon the apricot kernel, a rich source of Laetrile, which typically provides them with at least 150 – 250 mg "B17"/day. (3)

Among the Eskimaux living on their native diet, cancer was also so rare that it prompted famed anthropologist/explorer V. Stefhanson to write a book on the subject: "The Friendly Arctic" Description of (!!) Krebs' new therapy was published in the Journal of the AMA, the bible of the AMA, the doctors wondered if the Eskimaux' diet was perhaps, which is eaten year-round. The contents of caribou stomachs, partially-digested grasses unusually rich in nitrilosides, are a prized delicacy among the Eskimaux. (3)

Dr. M. Navarro of Santo Tomas Univ. of Manila, was a world-famed oncologist who was also an early Laetrile clinical pioneer. "By 1977 he had linked the low incidence of cancer in the native populations of Mindanao [the Philippines] to the continual ingestion of many sources of vitamin B17. That rate, about 1 per 100,000 [less than 1% of the U.S. cancer rate], is even only than that of the cancer-free Hunzas in the nonvitalan Filipino north, where generations of Filipinos have subsisted on [nitriloside-rich] cassava, wild rice, wild beans, berries and fruits." (4)

In a letter to Dean Burk, Jon Lettelle head at that time of the Cytochemistry Dept. of the NCI, Krebs wrote concerning North American Indians: "I have analyzed from historical and anthropological records the nitriloside content of the diets of ... North American Indians.... Some of these tribes would ingest over 8,000 mg of vitamin B17 (nitrilosides) a day. My data on the Modoc Indians are particularly complete." (2) As an example of the low cancer incidence among Indians eating their high "B17" native diet, Krebs cited a report of the Modoc Indians by the scientists in a 1906 AMA, the "Dr. Hill," – the doctors wondered if the Indians' diet had anything to do with the fact that only 36 cases of malignant cancer were found out of 30,000 admissions to Canada, Arizona Mission Hospital... In the same population of white persons, the doctors also found a cancer rate of 1 in 1800." (12)

In his article for a. Berglas' book Cancer: Cause and Cure, medical missionary Dr. Albert Schweitzer wrote that "On my arrival in Gabon [Africa] in 1913, I was astonished to encounter no cases of cancer. I saw none among the natives two hundred miles from the coast.... I can not, of course, say positively that there was no cancer at all, but other frontiers doctors, I can only say that they also noted this must have been rare. Many of the animals in the native kraals died of cancer, but due to the difference in nutrition of the natives compared to the Europeans..." (13) Of course, such high nitriloside foods as cassava, millet, maize and sorghum are staples of the traditional African diet. Cassava may contain from 225 to 183 mg/kg of the nitriloside linamarin (11)

The world-wide epidemiological picture is consistent. Wherever "primitive people" eat their traditional natural diet, their intake of nitrilosides is high, and their cancer incidence is low. And when, as among many modern Eskimo, they gain easy access to and become reliant upon the "civilized" Western diet of sugar, white flour, and refined/preserved foods, their cancer incidence shoots up and approximates the high incidence of Euro-American people.

ANIMAL: LAETRILE TESTS

There have been various animal studies that suggest an anti-cancer effect from Laetrile : "...the ECNO Laboratories in California conducted several experiments [with Laetrile]... In their second study on carcinoma of rats (Walker 256), with amygdalin in doses of 500 milligrams per kilogram injected intraperitoneally on days one, three and six after [transplant] tumor take, the following results were found:

```
    DAYS ENDTUMAL TUME
Controlsin
    19,19,19,19,19,21,21,21,22,22,22,24,24,24,25,25,25,26,26,26,1
    1
    1
Treamed
    27,28,28,28,29,29,29,30,30,30,30,31,32,32,32,40,40,43 (t-.00469, 1977=41%*)
    1
    1
```

The mean survival time of the control rats was thus 23 days. With the amygdalin-treated rats, mean survival time was 38 days, i.e. a 70% increase over the controls. The survival time of every Laetrile-treated animal was greater than that of every control animal.

"...in a test by Dr. Paul Reitsauer, chief biochemist of the Manfred von Ardenne Institute, Dresden (East Germany), 20 of 40 H-strain mice were given bitter almonds in addition to their standard diet. Bitter almonds contain amygdalin. Of the 20 mice fed bitter almonds, 19 survived. Of the 20 mice fed bitter almonds, all 40 mice were inoculated with 1 million Ehrlich ascites [cancer] cells. The 20 control mice lived an average of 21.9 days following this injection. The 20 mice receiving the bitter almond supplement lived an average of 31.5 days, a 44% increase in survival time." (14)

In 1977, Dr. Vern L. van Breemen of Salisbury State College, Maryland, reported that the addition of apricot kernels [rich in Laetrile] to standard food in pilot experiments with special strains of mice bred to develop breast cancer and leukaemia showed impressive differences both in terms of developing the disease and increased survival times between the animals that didn't receive the apricot kernels and those that did. When he reported his early findings... seven of the animals in the leukaemia control group and five in the breast cancer [control] group had died, while none of the mice on the kernels had. Ultimately only one of the mammary cancer mice developed any growing tumor, and, while the leukaemia mice were responsive in terms of total symptoms, leukaemia-prone mice that ate the apricot kernels enjoyed life extensions up to 50% over what would normally be expected." (10)

Veteran cancer researcher Kanematsu Sugiura (who had a 4-volume set of his collected scientific papers published in 1963) performed three sets of experiments between September 1970 and June 1972 "to determine whether amygdalin has any effect on the growth of transplantable cancers." He and associates at Sloan Kettering Institute, he said that "The results clearly show that amygdalin significantly inhibits the appearance of lung metastases in mice bearing spontaneous mammary tumors and increases significantly the inhibition of the growth of the primary tumor over the inhibition of tumor growth in the untreated animals." (15)

These are just some of the Laetrile animal studies yielding positive results, while they hardly prove Laetrile to be a "cure" for cancer (which scientific Laetrile proponents have never claimed it to be), they clearly evidence cancer inhibition.

HUMAN LAETRILE CLINICAL EXPERIENCE

In 1962 Dr. John Morrone reported his results from using Laetrile with 10 patients suffering from "inoperable cancer." The treatments ranged from 4 to 43 weeks in length, and a range of 5 to 133 grams Laetrile was given through intravenous injections. Morrone concluded his report: "The use of Laetrile... in 10 cases of inoperable, advanced cancer in humans, provided objective evidence of tumor regression in 4 cases, control of neoplastic growth in 2 cases, arrest of malignant growth, and reduction of adenopathy [swollen lymph nodes]. The results suggest regression of the malignant lesion... No other side effects [other than transient episodes of low blood pressure] were noted during the administration of Laetrile, and no toxic effects were observed in any of the patients in all cases." (16)

In 1974, PE. Brisol published his results from treating cancer patients with Laetrile between 1974 and 1971. He used a combination of intravenous and oral Laetrile. Intravenous doses started with 3 grams and worked up to 9 grams. After a period of months, oral Laetrile, 1 gm at bedtime, was begun in place of the injections. Bisol also used various nutrient supplements including vitamin enzymes, as well as a special diet, which was basically low in animal fat. Of a series of 180 patients with primary cancer [non-metastasized, confined to a single organ or tissue] 80 were still alive in 1991 when he compiled his treatment results. At that time 100 patients had been followed for 5 years, 80 for 10 years, while 40 had a follow-up from 5 to 19 years. Of the 42 patients who had died by 1991, 23 died from their cancers, 12 from unrelated causes, and 7 died of 'cause unknown.'(9)

Among his metastatic cancer patients, 32 of 108 died from their disease, while 6 died of unrelated causes, and 4 "cause unknown." Of his 61 patients still alive in 1981, 18 had a follow-up between 2 and 5 years, 30 between 5 and 10 years, 13 for 10 years. (9)

Bisol's results are impressive. Some of the individual patients discussed in his book were still alive (and well) 15-18 years after their initial Laetrile treatment. Bisol also notes that none of the cancer diagnoses were made by him (a small town, "family doctor") – all patients had diagnoses from other physicians. Many had already suffered the ravages of standard "cut-burn-and-poison" (surgery/X-ray/chemotherapy) oncological medicine before being given up as hopeless cases by orthodox doctors.

Other physicians who have worked with Laetrile have also reported favorable results using it. Thus Manuel Navarro, M.D., former professor of medicine and surgery at the Univ. of Santo Tomas, Manila, wrote in 1977: "... I have used Laetrile in the treatment of various types of cancer, and have seen during these years some of the cases I have been using Laetrile amygdalin in the treatment of my cancer patients. During this eighteen-year period I have treated a total of over five hundred patients with Laetrile amygdalin in the treatment of various malignancies, including the oral and the I-E The majority of my patients receiving Laetrile-amygdalin have been in a terminal state when treatment with this material commenced.

"It is my carefully considered clinical judgement, as a practicing oncologist and researcher in this field, that I have obtained most significant and encouraging results with the use of Laetrile amygdalin in the treatment of my cancer patients, and that these results are comparable or superior to the results I have obtained with the use of the more toxic standard cytotoxic agents." (11)

Dr. Ernesto Contreras has used Laetrile as a cornerstone of his cancer practice since 1963. He remarks that "For the prevention of cancer and the maintenance of remission, there is nothing as effective as Laetrile. This substance proves its use indefinitely while surgery, radiation and chemotherapy can only be administered for a limited time.... In the majority of cancers that occur more frequently, such as cancers of the lung, breast, colon, ovaries, stomach, esophagus, prostate, and the lymphomas, are much helped by Laetrile." (17)

Dr. Michael Schacter, who has used Laetrile for 20 years with cancer patients, remarks that "As part of a comprehensive health-enhancing program, amygdalin is a useful natural substance for fighting cancer." (18) Dr. Schacter's program for using Laetrile "in acutely-cytotoxic is a before-aborted form of cytotoxic) along with amygdalin, to maximize the body's ability to detoxify any cyanide released from the Laetrile." (18)

Dr. Douglas Brodie also uses Laetrile to treat his cancer patients. "After years of observing patients using amygdalin, we can say with complete assurance that it is neither toxic nor useless. Nor do we find it to be a cure for cancer. Amygdalin is a food, a substance which, we were told during frequent trips to Russian submissions of [SIA]." (22) They reported 19/57 inoperable terminal cancer patients "responded completely;" while 10 patients responded partially (i.e. greater than 50% tumor reduction). (23) Drs. Richardson and Sperti reported in 1956 that 4 of 10 inoperable cancer patients that is between them were given to BA in the body, to achieve a positive response rate in 10/24 cancer patients. "Careful monitoring showed no toxic action of BG at these large doses. Complete necrotic liquefaction of tumour, without any damage to surrounding tissue, was seen in 2 of 3 cases in which histological [microscopic tissue] examination was feasible." (34)

Dean Burk declared in 1971 at the Seventh International Congress of Chemotherapy in Prague: "In vitro tests with Ehrlich ascites carcinoma 2 cancers (1 cell culture) revealed that Laetrile alone destroyed some but not all of the cancer cells [BA] alone killed twenty percent, a combination of the two was effective against all the cells. Amygdalin with glucosidase... added also succeeded in killing 100 percent of the ascites tumor cells, due to the freeing of the same 2 chemicals (1) Thus Laetrile may actually kill cancer cells through a synergistic cytotoxic reaction between its two key breakdown products, cyanide and benzaldehyde.

THE SAFETY OF LAETRILE

Both human and animal data have shown the relative non-toxicity of Laetrile. A 1980 report stated that "Amygdalin given to male Swiss-Webster mice...at 3g/kg., was able to protect against the diabetogenic action of alloxan...amygdalin...can be tolerated by experimental animals at rather high doses." (26)

"In a series of tests on adult mice, Dr. Dean Burk reported that they could live in perfect health to extreme old age when their normal diet consisted of fifty percent whittled apricot kernels...Swiftly accepted each mouse's voluntary consumption of apricot kernels as a measure of its daily dose of Laetrile-vitamin B17... Monroe in his 1962 paper specifically commented on the absence of side-effects from Laetrile, while Brizel makes no mention of toxic side-effects among his patients. Drs. Krebs, Contreras, and Meyer personally report no side effects in their patients." (27)

Ironically, one record of Laetrile's high degree of safety, when properly used, was provided by a group of Laetrile opponents, led by Dr. Charles Moertal. In 1981 in JAMA, Moertal and co-workers wrote: "In our study, intravenous amygdalin was found to be free of clinical toxicity and no cyanide could be detected in the blood.... Amygdalin is the fundamental component of amygdalin products that are widely used in laetrile therapy. Laetrile therapy is said to be of significant benefit to patients with cancer. Our study, however, failed to confirm this." (28) This is further evidence that Laetrile's "timed release," "special delivery to cancer cells" action should generally be of low toxicity, since cyanide normally dissociates from free cyanide in tissues, unlike Laetrile.

The lengths that Laetrile opponents would go to in an attempt to discredit Laetrush through the "cyanide toxicity scare" was illustrated by the infamous 1978 "Laetrile Toxicity Studies in Dogs," (29) 10 dogs were force fed a special mixture of 1.4 grams Laetrile combined with a finely ground raw almond paste/water mixture, which had been pre-irradiated at body temperature in blood bags for 15-60 minutes. Almonds are one of the highest beta-glucosidase (i.e. Laetrile cyanide-releasing) – containing foods known. Incubating Laetrile with an almond/water paste at body temperature for 15-60 minutes will thus serve to pre-release high levels of cyanide from the Laetrile. Thus the dogs were fed high quantities of free cyanide, and the symptoms of the dogs were neurologically impaired, while 6 died. What this experiment proved is that large amounts of hydrogen cyanide, force-fed, are toxic. This is the basis of the so-called "gas chamber" used to execute criminals in some American states, although there the hydrogen cyanide is produced by dropping potassium cyanide pellets into acid. The experimental results merely duplicated, in a roundabout way, the efficacy of the gas chamber. They did not prove anything about the normal action of Laetrile, taken orally in relatively low doses on an empty stomach, as directed by practicing physicians. Incubating Laetrile with almonds is not the same as eating almonds, or the cyanide that everyone who chews a car without airbags at 120 miles per hour into a brick wall without wearing a seatbelt will be killed!

Another protective mechanism (aside from rhodanese) humans have when taking Laetrile orally (on an empty stomach) is through the interaction of cyanide with stomach hydrochloric acid. The pioneering work of Dr. Thomas and Hogle, like human beings, ... have only one stomach which is strongly acid due to the presence of hydrochloric acid. This acid reacts with hydrocyanic acid [cyanide] to form much less toxic substances like acetic acid [vinegar] and ammonium chloride thereby causing an almost immediate detoxification as soon as the hydrocyanic acid is liberated from the glucoside [i.e. Laetrile]." (4)

LAETRILE: SAFE USAGE

When Laetrile is used therapeutically, it is usually given either intravenously, at doses from one to nine grams, or orally, at doses of 500mg, two to four times daily. To maximize the safety and effectiveness of oral Laetrile, it is imperative that it be taken on an empty stomach, either two hours before or three hours after a meal. Laetrile should never be taken with raw almonds or raw almond products, since they are a source of beta-glucosidase, which can prematurely release hydrocyanic acid prome. According to Krebs (the "father" of Laetrile), approximately 50-200 mg/day of Laetrile, taken like vitamins (which Krebs believed Laetrile to be) on an open-ended, on-going basis, will provide a cancer-preventive dosage. Laetrile therapy has not eaten for at least three hours before retiring, taking a small Laetrile preventive dose at bedtime may be the best strategy. Laetrile ingestion may occasionally cause a temporary low blood pressure reaction due to formation of thiocyanate, a powerful blood pressure lowering agent. (30)

References

1) Krebs, E.T. Jr. (1970) "The nitrilosides (vitamin B-17): Their nature, occurrence and metabolic significance" *J Appl Nutr* 22: 75-86.

2) Budavari, S., ed. The Merck Index. Whitehouse Station, NJ: Merck Research Laboratories. P101.

3) Krebs, E.T. Jr. "The Nitrilosides in plants and animals" in Vitamin B17, Culbert, M. New Rochelle: Arlington House, 1974. P. 145-64.

4) Cha, O.L. "The role of hydrocyanic acid in nutrition," in World Review of Nutrition and Dietetics, vol. 11, Bourne, G.H., ed. Basel: S. Karger, 1969. P. 170-98.

5) Hoxsentuff, T. (1945) Gazette Medicale de Paris, 13: 677-82.

6) Hoxsentuff, T. (1946) Jour Chirurgie und Augenheilkunde, 20: 7-28.

7) Krebs, E.T. Jr. "Nitrilosides (laetrile)," in Vitamin B17, op. cit. P.189-204.

8) Bricot, P.E. Alive and Well. Westlake Village, CA: American Media, 1994.

9) Steffanson, V. Cancer: Disease of Civilization? NYC: Hill and Wang, 1960.

10) Culbert, M. What the Medical Establishment Won't Tell You That Could Save Your Life. Virginia Beach: Donning Co., 1983.

11) Griffin, G.E. World Without Cancer. Westlake Village, CA: American Media, 1997.

12) Griffin, G.E. Private Papers Pertaining to Laetrile. Westlake Village, CA: American Media, 1997.

13) Berglas, A. Cancer: Cause and Cure. Paris: Pasteur Inst., 1957.

14) Moss, R.W. The Cancer Industry. Brooklyn: Equinox Press, 1999.

15) Cullton, B.J. (1973) "Sloan-Kettering: The Trials of an Apricot Pit – 1973" Science 182: 1000-03.

16) Morrone, J.A. (1962) "Chemotherapy of Inoperable Cancer" Exp Med Surg 20: 299-308.

17) Navarro, M. et al. eds. An Alternative Medicine Definitive Guide to Cancer. Tiburon, CA: Future Medicine Pub., 1997.

18) Burk, D. and Harper, H.A. (1970) "Problems of early cancer diagnosis and therapy" Aggressologie 11: 1-7.

Disclaimer
These statements have not been evaluated by the Food and Drugs Administration.
These products are not intended to diagnose, treat, cure, or prevent any disease. See our terms and conditions for more information.

IAS sponsors and supports the following organizations: